Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...

Safety and efficacy data on the investigational subcutaneous formulation of ORENCIA in adults with moderate to severe rheumatoid arthritis to be presented at the American College of Rheumatology ...

(NAPSI)ORENCIA (abatacept) is the first and only biologic for the treatment of adults with moderate to severe rheumatoid arthritis (RA) available in both self-injectable (under the skin) and ...

The FDA has approved a subcutaneous formulation of Orencia (abatacept; Bristol-Myers Squibb) for the reduction of signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA). This ...

Medicinal products, including ORENCIA, which affect the immune system, may affect host defences against infections and malignancies. Serious infections, at least possibly related to treatment, were ...

NEW YORK Patients with rheumatoid arthritis derive about as much benefit from a weekly injection of a biotech drug made by Bristol-Myers Squibb for the disease as they do from receiving it via IV on a ...

Please provide your email address to receive an email when new articles are posted on . Bristol-Myers Squibb Company announced Orencia intravenous infusion and subcutaneous injection in combination ...

The FINANCIAL — Bristol-Myers Squibb Company on September 5 announced that the European Commission has approved ORENCIA (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, in ...

A greater response to Orencia was observed in the trial regardless of prior anti-TNF treatment and other non-biologic DMARD therapy. The approval for the new indication was based on results from two ...

August 2, 2011 — The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of abatacept (Orencia, Bristol-Myers Squibb Co) for the treatment of adults with moderate-to-severe ...